The OHRP issued draft guidelines requiring disclosure of all risks of standard treatments in comparative-effectiveness research. The authors argue that such risks are not risks of participation in research and that the proposal will confuse and mislead patients.
No takes yet. Share an insight, caveat, or question.
Lantos et al. (2014) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: